Biogen Idec seeks regulatory approval for rFVIIIFc to treat Hemophilia A
Driving into work this morning, I heard that Biogen Idec is seeking FDA approval for a new breakthrough drug to treat Hemophilia A. The drug, a recombinant factor VIII Fc fusion protein (rFVIIIFc),...
View ArticleGetting clotting factors to last longer in the blood
The BCH blog Vector talks about the progress of rFIXFc, a recombinant hybrid of Factor IX and an Fc receptor fragment, a new long lasting clotting factor which recently passed a phase 3 clinical trial....
View Article
More Pages to Explore .....
